Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory's experience: Unsatisfactory assay reproducibility.
Journal:
Clinical biochemistry
Published Date:
May 7, 2025
Abstract
INTRODUCTION: Serum protein electrophoresis and serum free light chain (SFLC) assays are standard methods for monitoring patients with multiple myeloma (MM). However, patients with non-secretory MM often require invasive bone marrow biopsies to monitor treatment response and disease progression. Recently, serum soluble B-cell maturation antigen (sBCMA) has been proposed as an alternative biomarker for monitoring of MM, including non-secretory disease. We aimed to optimize the performance of and validate a serum sBCMA enzyme-linked immunosorbent assay (ELISA) from R&D Systems for research and eventual clinical use.
Authors
Keywords
No keywords available for this article.